Mary Kay Fenton is CFO at ACHILLION PHARMACEUTICALS INC (ACHN). They have made 2 open-market trades across 2 companies since 2011, most recently 2026-06-30.
CIK 0001378589
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $10K since 2016, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TALS | 68,054 | $1.9M |
| CGEM | 127,921 | $1.7M |
| ACHN | 2,500 | $17K |
| Total | $3.5M |
Shares reported on the most recent Form 4, priced at the 2026-07-02 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CGEM | SELL | 2026-02-20 | 2026-02-23 | $13.62 | $60K | +11.1% | +0.0% | +10.1% |
| ACHN | BUY | 2016-12-05 | 2016-12-05 | $4.11 | $10K | -4.8% | +0.0% | -7.0% |
| ACHN | SELL · 10b5-1 | 2015-12-28 | 2015-12-30 | $10.08 | $438K | -25.7% | -35.9% | -28.3% |
| ACHN | SELL · 10b5-1 | 2015-01-23 | 2015-01-23 | $16.00 | $210K | -25.7% | -1.9% | -1.9% |
| ACHN | SELL · 10b5-1 | 2012-01-09 | 2012-01-11 | $11.22 | $168K | -25.7% | -1.9% | -1.9% |
| ACHN | SELL · 10b5-1 | 2011-04-05 | 2011-04-06 | $7.50 | $32K | -25.7% | -1.9% | -1.9% |
| ACHN | SELL · 10b5-1 | 2011-03-30 | 2011-04-01 | $7.50 | $30K | -25.7% | -1.9% | -1.9% |
| ACHN | SELL · 10b5-1 | 2011-01-13 | 2011-01-18 | $5.00 | $44K | -25.7% | -1.9% | -1.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.